{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T02:12:59Z","timestamp":1790475179423,"version":"4.1.0"},"reference-count":27,"publisher":"The Journal of Rheumatology","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2011,7]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To evaluate the safety and efficacy of rituximab (RTX) in juvenile dermatomyositis (JDM) in off-trial patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>We conducted a multicenter prospective study of patients with JDM included in the French Autoimmunity and Rituximab (AIR) registry.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Nine patients with severe JDM were studied. The main indication for RTX treatment was severe and\/or refractory muscle involvement (7 patients), severe calcinosis (1 patient), or severe chronic abdominal pain associated with abdominal lipomatosis (1 patient). RTX was associated with corticosteroids, immunosuppressive drugs, and plasma exchange therapy in 9\/9, 5\/9, and 2\/9 patients, respectively. Mild infections of the calcinosis sites occurred in 2 patients and an infusion-related event in 1. Complete clinical response was achieved in 3\/6 patients treated with RTX for muscle involvement. In these responders steroid therapy was stopped or tapered to &lt; 15% of the baseline dosage, with no relapse, with a followup ranging from 1.3 to 3 years. Calcinosis did not improve in the 6 affected patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>This small series suggests that rituximab may be effective for treating muscle and skin involvement in a small subset of children with severe JDM, and that its safety profile was satisfactory. Further studies are needed to identify predictive factors of response to RTX in patients with severe JDM.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.101321","type":"journal-article","created":{"date-parts":[[2011,6,16]],"date-time":"2011-06-16T05:06:43Z","timestamp":1308200803000},"page":"1436-1440","source":"Crossref","is-referenced-by-count":85,"title":["Safety and Efficacy of Rituximab in Severe Juvenile Dermatomyositis: Results from 9 Patients from the French Autoimmunity and Rituximab Registry"],"prefix":"10.3899","volume":"38","author":[{"given":"BRIGITTE","family":"BADER-MEUNIER","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00c9L\u00c8NE","family":"DECALUWE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CHRISTINE","family":"BARNERIAS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ROMAIN","family":"GHERARDI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PIERRE","family":"QUARTIER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ALBERT","family":"FAYE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"VINCENT","family":"GUIGONIS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANNE","family":"PAGNIER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KARINE","family":"BROCHARD","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JEAN","family":"SIBILIA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JACQUES-ERIC","family":"GOTTENBERG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CHRISTINE","family":"BODEMER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2011,6,15]]},"reference":[{"key":"2018112909263854000_38.7.1436.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60955-1"},{"key":"2018112909263854000_38.7.1436.2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21669"},{"key":"2018112909263854000_38.7.1436.3","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.6.763"},{"key":"2018112909263854000_38.7.1436.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2007.05.011"},{"key":"2018112909263854000_38.7.1436.5","doi-asserted-by":"crossref","unstructured":"Haroon M Devlin J . Rituximab as a first-line agent for the treatment of dermatomyositis. Rheumatol Int 2010 Mar 26. [Epub ahead of print]","DOI":"10.1007\/s00296-010-1458-6"},{"key":"2018112909263854000_38.7.1436.6","doi-asserted-by":"publisher","DOI":"10.1002\/art.20849"},{"key":"2018112909263854000_38.7.1436.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.05.068"},{"key":"2018112909263854000_38.7.1436.8","first-page":"1021","article-title":"Rituximab as therapy for refractory polymyositis and dermatomyositis","volume":"33","author":"Noss","year":"2006","journal-title":"J Rheumatol"},{"key":"2018112909263854000_38.7.1436.9","first-page":"1230","article-title":"Long lasting remissions after treatment with rituximab for autoimmune myositis","volume":"35","author":"Feist","year":"2008","journal-title":"J Rheumatol"},{"key":"2018112909263854000_38.7.1436.10","first-page":"887","article-title":"Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy","volume":"26","author":"Sultan","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909263854000_38.7.1436.11","first-page":"1009","article-title":"Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature","volume":"27","author":"Rios Fern\u00e1ndez","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909263854000_38.7.1436.12","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.029694"},{"key":"2018112909263854000_38.7.1436.13","doi-asserted-by":"publisher","DOI":"10.1002\/art.22856"},{"key":"2018112909263854000_38.7.1436.14","doi-asserted-by":"publisher","DOI":"10.4076\/1757-1626-2-6609"},{"key":"2018112909263854000_38.7.1436.15","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2009-3395"},{"key":"2018112909263854000_38.7.1436.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200306263482620"},{"key":"2018112909263854000_38.7.1436.17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-186999"},{"key":"2018112909263854000_38.7.1436.18","first-page":"603","article-title":"Defining clinical improvement in adult and juvenile myositis","volume":"30","author":"Rider","year":"2003","journal-title":"J Rheumatol"},{"key":"2018112909263854000_38.7.1436.19","doi-asserted-by":"publisher","DOI":"10.1002\/art.21291"},{"key":"2018112909263854000_38.7.1436.20","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20280"},{"key":"2018112909263854000_38.7.1436.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.23960"},{"key":"2018112909263854000_38.7.1436.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2006.01.041"},{"key":"2018112909263854000_38.7.1436.23","doi-asserted-by":"publisher","DOI":"10.1002\/art.24411"},{"key":"2018112909263854000_38.7.1436.24","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/acr.20071","article-title":"Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children\u2019s Arthritis and Rheumatology Research Alliance Consensus Conference","volume":"62","author":"Huber","year":"2010","journal-title":"Arthritis Care Res"},{"key":"2018112909263854000_38.7.1436.25","unstructured":"Pediatric Rheumatology INternational Trials Organization . Juvenile dermatomyositis trial. [Internet. Accessed March 14, 2011.] Available from: http:\/\/www.printo.it\/project_ongoing_detail.asp?ProjectID=14"},{"key":"2018112909263854000_38.7.1436.26","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20269"},{"key":"2018112909263854000_38.7.1436.27","doi-asserted-by":"crossref","unstructured":"Dagher R Desjonqu\u00e8res M Duquesne A Quartier P Bader-Meunier B Fischbach M Mycophenolate mofetil in juvenile dermatomyositis: a case series. Rheumatol Int 2010 Dec 9. [Epub ahead of print]","DOI":"10.1007\/s00296-010-1653-5"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.101321","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T16:40:48Z","timestamp":1712508048000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.101321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,15]]},"references-count":27,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2011,7,1]]},"published-print":{"date-parts":[[2011,7]]}},"alternative-id":["10.3899\/jrheum.101321"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.101321","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,15]]}}}